早产新生儿的独家母乳和早期血管老化风险因素 (NEOVASC) (NEOVASC)
早产新生儿纯母乳饮食对早期血管老化危险因素 (NEOVASC) 的影响
Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.
研究概览
详细说明
Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.
The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:
- An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
- Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.
The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Ursula Kiechl-Kohlendorfer, MD, MSc
- 电话号码:+43 512 504 27309
- 邮箱:ursula.kohlendorfer@i-med.ac.at
研究联系人备份
- 姓名:Wolfgang Mitterer, MD
- 电话号码:+43 670 2021490
- 邮箱:wolfgang.mitterer@student.i-med.ac.at
学习地点
-
-
Tyrol
-
Innsbruck、Tyrol、奥地利、A-6020
- 招聘中
- Medical University of Innsbruck
-
接触:
- Ursula Kiechl-Kohlendorfer, MD, MSc
- 电话号码:+43 512 504 27309
- 邮箱:ursula.kohlendorfer@i-med.ac.at
-
接触:
- Wolfgang Mitterer, MD
- 邮箱:wolfgang.mitterer@student.i-med.ac.at
-
首席研究员:
- Christoph Binder, MD
-
首席研究员:
- Martin Wald, MD
-
首席研究员:
- Burkhard Simma, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Preterm-born group:
Inclusion Criteria:
- Extremely preterm infants with a birth weight of 500-1250g.
- Feeding is NPO or exclusive human milk prior to enrollment.
- Parent(s) willing to sign informed consent.-
Exclusion Criteria:
- Infants with a birth weight <500g or >1250g
- Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
- Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
- Presence of major congenital malformation.
- Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
- Parent(s) not willing to sign informed consent.
- Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).
Term-born group:
Inclusion criteria
- Term-born children with an adequate birth weight
- Parent(s) willing to sign informed consent
Exclusion criteria
- Subjects with acute or chronic illness
- Parent(s) not willing to sign informed consent
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Randomized study product group
receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
有源比较器:Randomized control group
receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
无干预:Term control group
Term-born controls as a reference group for outcome parameters |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fasting blood glucose
大体时间:"First day of life" up to "five years of life"
|
Primary outcome is the difference in fasting blood glucose at five years of age |
"First day of life" up to "five years of life"
|
|
Blood pressure
大体时间:"First day of life" up to "five years"
|
Primary outcome is the difference in blood pressure at five years of age |
"First day of life" up to "five years"
|
|
Distensibility of aorta
大体时间:"First day of life" up to "five years"
|
Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age |
"First day of life" up to "five years"
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fasting blood glucose
大体时间:"First day of life" up to "24 months"
|
Secondary outcome is fasting glucose at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
Blood pressure
大体时间:"First day of life" up to "24 months"
|
Secondary outcome is blood pressure at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
BMI
大体时间:"First day of life" up to "five years"
|
Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"First day of life" up to "five years"
|
|
Insulin sensitivity
大体时间:"First day of life" up to "five years"
|
Secondary outcome is insulin sensitivity at five years of age |
"First day of life" up to "five years"
|
|
Lipid profile
大体时间:"First day of life" up to "five years"
|
Secondary outcome is lipid profile at five years of age |
"First day of life" up to "five years"
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fasting blood glucose
大体时间:"five years of age"
|
Difference in fasting blood glucose between preterm- and term-born children at five years of age |
"five years of age"
|
|
Blood pressure
大体时间:"five years of age"
|
Difference in blood pressure between preterm- and term-born children at five years of age |
"five years of age"
|
|
Distensibility of the descending aorta
大体时间:"five years of age"
|
Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children |
"five years of age"
|
|
BMI
大体时间:"five years of age"
|
Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"five years of age"
|
|
Insulin sensitivity
大体时间:"five years of age"
|
Difference in insulin sensitivity between preterm- and term-born children at five years of age |
"five years of age"
|
|
Lipid profile
大体时间:"five years of age"
|
Difference in lipid profile between preterm- and term-born children at five years of age |
"five years of age"
|
合作者和调查者
合作者
调查人员
- 首席研究员:Ursula Kiechl-Kohlendorfer, MD, MSc、Medical University Innsbruck
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.